1179336-41-4 Usage
Description
(R)-8-(2-azido-1-hydroxyethyl)-5-(benzyloxy)-2H-benzo[b][1,4]oxazin-3(4H)-one is a chemical compound derived from benzoxazinone, featuring a hydroxyethyl group, an azido group, and a benzyloxy substituent. (R)-8-(2-azido-1-hydroxyethyl)-5-(benzyloxy)-2H-benzo[b][1,4]oxazin-3(4H)-one holds potential for various chemical reactions and may be of interest for applications in the medicinal and pharmaceutical industries. Further research and testing are required to fully comprehend its potential uses and properties.
Uses
Used in Pharmaceutical Industry:
(R)-8-(2-azido-1-hydroxyethyl)-5-(benzyloxy)-2H-benzo[b][1,4]oxazin-3(4H)-one is used as a chemical intermediate for the development of new pharmaceuticals due to its unique structural features and potential reactivity in chemical reactions.
Used in Medicinal Chemistry:
(R)-8-(2-azido-1-hydroxyethyl)-5-(benzyloxy)-2H-benzo[b][1,4]oxazin-3(4H)-one is used as a building block in the synthesis of novel bioactive molecules, potentially leading to the discovery of new drugs with improved therapeutic properties.
Used in Chemical Research:
(R)-8-(2-azido-1-hydroxyethyl)-5-(benzyloxy)-2H-benzo[b][1,4]oxazin-3(4H)-one serves as a subject of study in chemical research to explore its reactivity, stability, and potential applications in various chemical processes and reactions.
Check Digit Verification of cas no
The CAS Registry Mumber 1179336-41-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,7,9,3,3 and 6 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1179336-41:
(9*1)+(8*1)+(7*7)+(6*9)+(5*3)+(4*3)+(3*6)+(2*4)+(1*1)=174
174 % 10 = 4
So 1179336-41-4 is a valid CAS Registry Number.
1179336-41-4Relevant articles and documents
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists
Weichert, Dietmar,Stanek, Markus,Hübner, Harald,Gmeiner, Peter
, p. 2641 - 2653 (2016/06/08)
Aiming to discover dual-acting β2 adrenergic/dopamine D2 receptor ligands, a structure-guided approach for the evolution of GPCR agonists that address multiple targets was elaborated. Starting from GPCR crystal structures, we describ
